You are here: Industry Insights > Market News > Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences

pharmaceutical-technologyAugust 04, 2017

Tag: Innoviva , Seattle Genetics , PlasmaGen BioSciences

Favorites

US-based small molecule medicines provider Innoviva (formerly Advanced Medicine) has announced a private placement of convertible senior notes due 2025 to raise $175m.

Biotechnology company Seattle Genetics plans to acquire biopharmaceutical firm Bristol-Myers Squibb’s pharmaceutical manufacturing facility located in Bothell, Washington, US.

"Biotechnology company Seattle Genetics plans to acquire biopharmaceutical firm Bristol-Myers Squibb’s pharmaceutical manufacturing facility located in Bothell, Washington, US."

The acquisition will help the company to expand its antibody drug conjugate and immuno-oncology pipeline.

PlasmaGen BioSciences Private has secured $25m through a venture financing round led by Eight Roads Ventures India.

The Indian biopharmaceutical company will use the funds for the expansion of its product portfolio.

Previous:Latest Progress of PD-1 Inhibitors: Keytruda and Opdivo are close

Next:QS Pharma receives approval from European Medicines Agency

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>